Scholars Central

Conference abstract

Mechanism of high MW complexes formation by Verteporfin which can impair the growth of cancer cells

Authors: Eleni Konstantinou, Lucy H L Young, Demetrios G Vavvas

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Verteporfin (VP) was first used in Photodynamic therapy (PDT), where a non-thermal 689 nm light activates VP in the presence of oxygen to produce highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage. In addition, it has been shown that VP can interfere with the HIPPO pathway in the absence of light and inhibit the growth of hepatocellular carcinoma, retinoblastoma and uveal melanoma. More recently we observed that VP can lead to the formation of dimers and high molecular weight aggregates. In a series of experiments, uveal melanoma (MEL 270), human embryonic kidney (HEK) and breast cancer cells (MCF7) were treated with either low (1.25 ug/ml) or a high (7.5 ug/ml) dose of VP for 0, 6 and 24 hours. Dark and light conditions before and after lysis of the cells were examined in order to identify the exact cell cycle phase that the high molecular weight complexes occurred. We have demonstrated that VP aggregate formation requires light-activation and oxidization of VP. These high molecular weight complexes are toxic for the cells, leading to growth restriction and cell death. This work demonstrates yet another potential therapeutic mechanism of action of verteporfin.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmacovigilance.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Eleni Konstantinou”
  • BylineArticles whose byline prints “Lucy H L Young”
  • BylineArticles whose byline prints “Demetrios G Vavvas”